SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03
SinoMab BioScience Limited (SinoMab, or the Company, HKG: 3681), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases,…